1. South Korea Stocks

  2. •

    Health technology

  3. •

    Medical specialties
CG MedTech Co.Ltd.

CG MedTech Co.Ltd.

KKRX:056090
4,550.00
KRW
-130.00
(-2.78%)
79.61EPS
80.18P/E
660.86BMarket Cap
Nov 18Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
704.93
554.45
305.09
350.99
832.65
909.89
723.59
171.5
619.55
450.77
580.03
457.29
623.62
Basic EPS, GAAP
70
-30.8
-54.2
-172.8
-386.8
-49.4
-320
-22.4
-279
21
1
63
79.83
Free Cash Flow per Basic Share
-39.13
-248.77
-180.59
-95.87
-273.19
-76.37
49.98
0.03
-95.03
-53.15
11.74
-90.3
-282.86
Dividend per Share
- -
2.62
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
242.44
1,646.76
1,538.67
1,432.77
1,027.02
992.37
674.08
619.82
731.55
763.05
844.14
910.36
928.03
Tangible Book Value per Share
187.73
1,578.82
1,421.65
1,050.26
933.68
919.3
626.51
578.46
711.38
745.07
798.85
804.09
818.07
Basic Weighted Avg Shares
22
26
38
38
38
38
38
222
66
78
60
103
82
Sales/Revenue/Turnover
15,639
14,596
11,688
13,294
31,686
34,814
27,775
38,055
41,169
34,969
34,623
47,235
51,199
Operating Margin (%)
13.68
-8.47
-27.25
-40.17
-15.5
-3.29
-38.9
-2.99
0.98
8.74
-3.17
8.08
3.69
Depreciation Expense
709
889
1,290
1,683
2,833
2,245
2,406
2,162
2,201
1,853
1,692
2,264
2,987
Net Income, GAAP
1,553
-811
-2,076
-6,545
-14,719
-1,890
-12,283
-4,970
-18,540
1,629
60
6,508
6,554
Effective Tax Rate (%)
1.38
- -
- -
- -
- -
- -
- -
- -
- -
5.83
1,071.84
- -
- -
Profit Margin (%)
9.93
-5.56
-17.77
-49.23
-46.45
-5.43
-44.22
-13.06
-45.03
4.66
0.17
13.78
12.8
Working Capital
4,748
54,321
42,642
40,284
18,389
23,034
3,912
17,433
22,131
24,819
42,212
18,555
23,510
LT Debt
3,501
6,220
1,170
15,456
12,670
17,774
5,053
15,491
731
645
2,122
1,662
13,503
Total Equity
9,252
62,846
59,067
54,292
39,200
37,988
27,085
28,778
57,679
59,900
86,766
94,148
96,016
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
-1.65
14.2
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.61
-2.01
- -
- -
Return on Common Equity (%)
- -
-2.25
-3.41
-11.55
-31.49
-4.9
-37.75
-17.87
-42.99
2.76
0.08
7.18
7.12

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2,646
2,962
7,009
LT Borrowings
860
11,301
12,730
LT Finance Leases
803
686
773
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
103
103
103
Market Capitalization
603,033
1,128,105
660,858

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
35,083
41,753
44,814
Cash, Cash Equivalents & STI
10,844
14,963
10,752
Accounts Receivable, Net
7,254
7,835
8,274
Inventories
15,392
15,983
19,744
Total Current Liabilities
16,528
16,388
21,305
Payables & Accruals
- -
- -
- -
ST Debt
2,646
2,962
7,009
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.02%
32.78%
8.51%
Free Cash Flow
-9,369.06%
-18,719.5%
-1,431.15%
Net Income, GAAP
1,176.91%
2,162.04%
10,801.88%
Sales/Revenue/Turnover
18.74%
13.11%
36.43%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8,350
7,924
8,491
9,858
34,623
2025
11,758
12,630
11,345
11,501
47,235
2026
13,036
15,316
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-11
1
2
30.38
1
2025
5.03
11
14.91
159.12
63
2026
5.95
11
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Hyun-Seung Yu
Full Time Employees
118
Sector
Health technology
Industry
Medical specialties
Address
Uijeongbu-si South Korea
IPO Date
Nov 12, 2015
Website
cgmedt.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
CG MedTech Co.Ltd. is a South Korea-based technology and medical solutions provider primarily engaged in the development and deployment of financial information technology (IT) solutions, enterprise software systems, and medical devices and healthcare products. The company organizes its business operations across three primary segments: Financial IT Solutions, Medical Technology & Healthcare, and Hardware Distribution. Its product and service portfolio comprises core banking application software; next-generation electronic banking and mobile transaction platforms; automated teller machine (ATM) and cash dispenser (CD) control software; branch automation and teller terminal systems; electronic financial transaction processing and security software; enterprise systems integration (SI), maintenance, and technical consulting services; diagnostic, therapeutic, and aesthetic medical equipment; digital healthcare platforms; bio-technology and medical consumables; and the wholesale distribution of telecommunications equipment, enterprise servers, and computer peripherals. Founded in 1997 and headquartered in Seoul, South Korea, CG MedTech Co.Ltd. caters to commercial banks, specialized financial institutions, government agencies, enterprise clients, hospitals, and healthcare facilities primarily in South Korea, while expanding its distribution footprint internationally. The company operates as part of the CG Group corporate network, maintaining affiliations with related entities such as GNCO Co., Ltd. In recent strategic developments, the company changed its corporate name from Curocom Co., Ltd. to CG MedTech Co., Ltd., marking a corporate reorganization and strategic pivot aimed at accelerating growth within the medical technology, life sciences, and digital health markets. In tandem with this rebranding, the company broadened its corporate charter to encompass medical device manufacturing and healthcare distribution, restructured its internal divisions to optimize synergies between its stable financial IT business and expanding healthcare operations, and entered strategic alliances with healthcare technology partners to commercialize new medical and diagnostic solutions.